Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14740338.2016.1175429 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Intrahepatic cholangiocarcinoma (ICC) presents a significant clinical challenge due to its high fatality rate and limited surgical candidacy. With only 30-40% of patients eligible for surgery upon diagnosis, alternative therapies are imperative. This study assesses the efficacy of Yttrium-90 (Y-90) radioembolization for unresectable ICC patients in a non-university tertiary care center (NUTCC).
View Article and Find Full Text PDFRipple Effects of Early Life Stress on Vascular Health.
Hypertension
January 2025
Cardio-Renal Physiology and Medicine, Department of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, AL (C.E.K., G.C.K., J.S.P.).
The term early life stress encompasses traumatic events occurring before the age of 18 years, such as physical abuse, verbal abuse, household dysfunctions, sexual abuse, childhood neglect, child maltreatment, and adverse childhood experiences. Adverse psychological experiences in early life are linked to enduring effects on mental and physical health in adulthood. In this review, we first describe the effects and potential mechanisms of early life stress on the components of the vasculature.
View Article and Find Full Text PDFEculizumab treatment for Chinese patients with hemolytic paroxysmal nocturnal hemoglobinuria (PNH): efficacy and safety - a single-center study.
Hematology
December 2025
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People's Republic of China.
Objective: To evaluate the short-term efficacy and safety of eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in China.
Method: Data were retrospectively collected from patients with PNH who received at least 3 months of full-dose eculizumab. Changes in clinical and laboratory indicators after 1, 3, and 6 months of eculizumab therapy and at the end of follow-up were documented.
Improving the management of polycythemia vera patients eligible for cytoreduction: report of a multidisciplinary advisory board.
Curr Med Res Opin
January 2025
Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
Introduction: The management of patients with Polycythemia Vera (PV) traditionally includes low-dose aspirin, phlebotomy, and cytoreductive therapy for high-risk individuals. Recent evidence suggests that cytoreductive treatment may be warranted for patients with additional risk factors beyond the traditional criteria of a history of thrombosis and age over 60 years. Introducing new therapeutic agents, including ropeginterferon alfa-2b and ruxolitinib, enables a more personalized treatment approach tailored to individual patient characteristics.
View Article and Find Full Text PDFClozapine, relapse and adverse events: 10-year electronic cohort study in Canada: commentary, Kikuchi.
Br J Psychiatry
January 2025
Department of Psychiatry, Graduate School of Medicine, Tohoku University, Sendai, Japan; and Department of Psychiatry, Kodama Hospital, Ishinomaki, Japan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!